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Background: Successful treatment of HIV-positive children requires a high level of adher-
ence  (at least 95%) to highly active antiretroviral therapy. Adherence is inﬂuenced by factors
related to the child and caregivers.
Objectives: To evaluate children and caregivers characteristics associated to children’s adher-
ence.
Methods: Cross-sectional study, from September 2013 to June 2015, comprising a sample
of  caregivers of perinatally HIV-infected children, in the age group of 1–12 years, under
antiretroviral therapy for at least 6 months and on follow-up in two  AIDS reference cen-
ters  in Salvador, Bahia. Caregiver self-reports were the sole source of 4 days adherence and
sociodemographic information. Study participants who reported an intake >95% of pre-
scribed medication were considered adherents. A variable, (“Composed Adherence”), was
created to better evaluate adherence.
Results: We  included 77 children and their caregivers. 88.3% of the caregivers were female,
the  median age was 38.0 years (IQR 33.5–47.5), 48.1% were white or mixed, 72.7% lived in
Salvador and 53.2% had no ﬁxed income. The 4 days child’s adherence was associated only
to  caregivers that received less than a minimum salary (p < 0.05), 70.1% of the caregivers
had  less than four years of formal education, 81.8% were children’s relative and 53.2% of
the  caregivers were HIV positive. The caregiver’s pharmacy reﬁll, long-term adherence and
4  days adherence, were signiﬁcantly associated with composed adherence (p < 0.05). Child’s
long-term adherence was strongly associated to the 4 days child’s adherence referred by
caregiver (p < 0.001).
Conclusions: Our results suggest the need of improvement in HIV-infected children adher-ence, through reinforcement of the caregivers own adherence.
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Introduction
The introduction of effective new antiretroviral therapies in
the early 90s provided improved health and increased life
expectancy for HIV-infected children.1,2 However, to achieve
viral suppression, prevent disease progression and resistance
to antiretroviral drugs, at least 95% adherence to therapy is
required.3 Optimal adherence to therapy can be affected by
several child-related factors, including biomedical, psychoso-
cial, antiretroviral therapy and caregiver characteristics.4,5
Previous studies that assessed adherence to antiretrovi-
ral therapy in children showed that it varies from 57 to 81%,
depending on the deﬁnition and the method by which adher-
ence was veriﬁed. In two clinical protocols, which used the
self-report method to evaluate adherence to therapy, full
adherence was detected in 70–74% of the participants.6,7
Some caregiver’s characteristics can affect children’s
adherence to treatment. In the case of mother-to-child trans-
mission, death or severe disease of biological parents may
unable them to take care of the child. This is especially true
for mothers, who  usually have to deal with the guilt associ-
ated with HIV transmission, and may have other comorbidities
such as depression, which results in delayed child’s care. In
consequence, children care can be transferred to another fam-
ily member, or even to institutions.8
The antiretroviral treatment is complex and requires con-
stant changes in dosage according to the weight of the child,
especially those who  take syrups or powders that need pre-
vious reconstitution. Caregiver’s low educational level may
be related to non-adherence to treatment, due to the lack of
prescription understanding. A Romanian study detected an
association between poor adherence and low educational level
of caregivers, which was also associated with treatment aban-
donment, in 40 cases of families with children on highly active
antiretroviral therapy (HAART).9
It is remarkable that in resource-limited settings many  HIV-
infected children come from underprivileged families without
ﬁnancial conditions to provide proper food supply.10 This may
be related with caregiver’s decision to skip a dose of a speciﬁc
ARV drug, when the child was not fed, because it was rec-
ommended to be administered with food, or after a meal.10
Lack of enough money to pay for transportation to the phar-
macy  for antiretroviral drugs withdrawal, can be also a cause
of non-adherence.10–13
The main objective of this study was to evaluate the
relationship between different caregivers characteristics (fos-
ter parents, biological parents, and relatives), and children’s
adherence by using two different approaches: child’s “com-
posed adherence” and the 4-day child’s adherence, as reported
by caregivers.
Material  and  methods
Study  settingThis study was conducted at CEDAP (Diagnostic Center, for
assistance and research in HIV) and HUPES (Professor Edgard
Santos University Hospital), two referral centers for care of 1 6;2  0(5):429–436
HIV-infected children, in Salvador, Brazil. CEDAP is a public
service, composed by a multidisciplinary team, which pro-
vides assistance to individuals with HIV/AIDS. The HUPES,
is a large tertiary hospital that includes both, inpatient and
outpatient AIDS clinics.
Study  design  and  population
This cross-sectional study was conducted from September
2013 to June 2015. The inclusion was restricted to HIV peri-
natally infected children, aged one to 12 years old, under
antiretroviral therapy for at least six months and regular care
at HUPES or CEDAP, and to their caregivers. All individuals
in charge of routine administration of antiretroviral drugs to
enrolled children were identiﬁed as caregivers.
A total of 141 children were under care in the two-referral
centers. Thirty-four of them were excluded: 21 (14.9%) were
older than 12 years, three (2.1%) died, three (2.1%) were trans-
ferred to another reference center, two (1.4%) were not on
HAART, three were not infected by vertical transmission, and
two (1.41%) caregivers refused to participate.
From the 107 eligible children, 30 participants were
excluded: 16 were not adherent to the treatment (irregular ART
pharmacy reﬁll and persistently high viral load), nine were not
available to meet the investigators, two had abandoned treat-
ment, one was transferred to another reference center at the
beginning of the study, and the remaining two  could not be
contacted. Thus, 77 (72.0%) children were evaluated (Fig. 1).
Questionnaire  design  and  adherence  assessment
Caregiver  demographic  characteristics
Caregivers were asked to answer a structured questionnaire
with sociodemographic information: relationship with the
child (parent, relative, or adoptive caregiver), caregiver HIV
status, age, gender, residence (state capital city or coun-
tryside), race/ethnicity (white/mixed or black), functional
status (employed, self-employed, unemployed, housewife,
retired, or pensioner), family’s monthly income (no household
income/less than one Minimum Salary or one to ﬁve mini-
mum salaries), formal education (no school/primary school or
secondary school/Higher education), use of alcohol or illicit
drugs, and disclosure of HIV status to at least one member of
the family.
Electronic  medical  chart  review
Medical charts were reviewed to obtain the most recent
HIV viral load, CD4+ lymphocyte count, and ARV regimen.
Pharmacy reﬁll records were collected for all antiretroviral
medications prescribed in the last six months.
Adherence  to  ARV  medication
Caregiver’s self-reports were the sole source of the 4-day
adherence data. For the analysis of adherence, the “Adher-
ence Follow-up Questionnaire”, previously developed by  the
Aids Clinical Trial Group (ACTG) and drawn up originally in
English,14 was carefully translated and adapted to the local
language, into two questionnaires, one for evaluation of chil-
dren’s adherence and the other for adherence of HIV infected
caregivers.
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  30 individuals could no t be re ached: 
16 were  not  adherent  (missing visits);
02 abandoned  the  treatment;
01 was  transferred  at  the beggining  of  the  stud y;
02 the situation  was unknown;
09 were  adherent,  but  unavailable  to  meet     
 interviewer.
77 children were included .
Composed Adheren ce 4 days  child´s  adheren ce
141 perinatall y HIV-infecte d childr en, a ged 1-12  years
old and with at  least  6 months  of  HAART.
34 individuals were excluded: 
21 had alread y completed  12 years old;
03 had  alread y died;
03 trans ferred  to  another  unit; 
02 did  not  use  HAART;
03 were  not  infected  by  vertical  tran smission; 
02 caregivers  refused  to participate.
107 children were  defined  as 
eligible.
47 children were  
adh erent
30 children were not  
adh erent
62 children were  
adh erent
15 children were  
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aFig. 1 – Selection of participan
In both adherence questionnaires (caregivers and chil-
ren), caregivers were asked to describe the ART regimen, to
eport on the number of missed doses for each medication
er day, during the past four days. In addition, caregivers were
sked the last time the medications were missed (past week,
ast 1–4 weeks, past month, past 1–3 months, >3 months ago)
s a measure of “long-term adherence”. Salvador-Bahia, 2013–2015.
Adherence for last four days, was calculated as the
number of doses taken in the last four days/total num-
ber of prescribed doses for those four days. One dose was
deﬁned as any administration of each drug, regardless of the
amount of pills. If the individual takes three medications
and each one of them is twice a day, it was consid-
ered six doses per day. Study participants who  reported an
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Table 1 – Criteria to deﬁne children as “adherent” or
“non-adherent” according to composed adherence
method, in Salvador-Brazil, 2013–2015.
4-Day child’s
adherence
reported by
caregiver
Pharmacy
reﬁlla
Viral
loadb
(copies/mL)
Composed
adherencec
≥95% Regular ≤200 Yes
≥95% Regular >200 Yes
≥95% Irregular ≤200 Yes
≥95% Not availabled ≤200 Yes
<95% Regular ≤200 Yes
<95% Irregular ≤200 No
<95% Irregular >200 No
<95% Not availablee >200 No
≥95% Irregular >200 No
a Pharmacy reﬁll was regular when the caregiver took the ARVs
for the child during the previous 6 months without missing and
irregular. When the caregiver did not took the ARVs for the child
during the previous 6 months at least 1 month.
b Copies/mL.
c Adherence developed by the combination of three adherence
measures (4-day child’s adherence, the pharmacy reﬁll and viral
load).
d Data was not available for 1 participant.
e Data was not available for 1 participant.intake of ≥95% of prescribed medication were considered
adherent and those with a reported intake of <95% were
classiﬁed as non-adherent. A question regarding compliance
with speciﬁc instructions for a given drug and how closely
these instructions were followed was also included in the
survey.
“Composed Adherence” was deﬁned as the combina-
tion of three adherence measures: 4-day child’s adherence
reported by caregiver (≥95% or <95%), pharmacy reﬁll in
the last six months (regular if antiretrovirals were taken
in the last 6 months without missing), and viral load (≤
200 or >200 copies/mL). Tables 1 and 2 summarizes these
deﬁnitions.
Statistical  analysis
The main outcome variable of this study was children’s adher-
ence. There were two  deﬁnitions of adherence: composed
adherence and the 4-day children’s adherence reported by
caregivers. The median values with interquartile ranges (IQR)
were used as measures of central tendency because con-
tinuous variables (caregivers’s age, children’s age, treatment
duration, and log10 HIV viral load) were not normally dis-
tributed. The comparison between these variables and study
groups (composed adherence and 4-day child’s adherence)
was also performed, by using the Mann–Whitney U-test. The
Fisher’s or chi-square tests were used to determine if cate-
gorical variables were signiﬁcantly associated with adherence.
A p-value below 0.05 was considered statistically signiﬁcant.
Statistical analyses were performed by using SPSS 20.0 (IBM
statistics). 1 6;2  0(5):429–436
Ethical  considerations
The present study was approved by the Health Research Ethics
Committee of Climério de Oliveira Maternity, in August 2013
(approval decision number 376.534).
Results
Sociodemographic characteristics of caregivers and their
association with the “composed adherence” and the 4-day
children’s adherence (reported by caregivers) are shown in
Table 2. Among the 77 caregivers interviewed, 88.3% were
female, the median age was 38.0 years (IQR 33.5–47.5), 48.1%
declared themselves as white or racially mixed, 72.7% lived in
Salvador and more  than a half (53.2%) had no ﬁxed income.
Family income of less than a minimum wage  (37.7%) was
associated to 4-day children’s adherence ≥95%, as reported
by caregivers (p < 0.05).
Regarding caregiver’s characteristics, 70.1% of them had
less than four years of formal education, 39.0% reported alco-
hol use, 81.8% were children’s relatives (parents, grandparents,
uncles, aunts) and 53.2% were HIV infected. Only one caregiver
was drug user.
As expected, the adherence factors of the HIV-infected
caregivers (caregiver’s pharmacy reﬁll, long term adherence
and 4-day self-reported adherence) were associated (p < 0.05)
to child’s “composed adherence”. Among the 41 HIV infected
caregivers, 15 (38.5%) were regular on pharmacy reﬁll. Of
these, 14 (93.3%) had children who fulﬁlled composed adher-
ence criteria. Furthermore, all children cared by caregivers
with long-term adherence (12) were adherent to therapy,
while among those cared by 27 caregivers that had 4-day
self-reported adherence ≥ 95%, only 20 (74.0%) were adherent,
according to composed adherence criteria. Most (56.4%) of the
HIV-infected caregivers were on non-nucleoside based HAART,
and 73.2% of them had disclosed their HIV serostatus to at
least one family member (Table 3).
Table 4 shows sociodemographic and treatment char-
acteristics of children that were associated to “Composed
adherence”, and 4-day child’s adherence reported by care-
givers. Most of the children (54.5%) were male, median age was
94.2 months (IQR 58.7–118.5). Regarding children’s antiretro-
viral regimens, 41.6% were using a combination of liquid
drugs and pills, and most of children were adherent (44.7%),
according to composed adherence. No association was found
between these factors. Children’s adherence, as reported by
caregivers, was high, with 80.5% of children presenting adher-
ence higher than 95%.
Among children included in the study, the median treat-
ment time was 39.7 months (IQR 24.0–67.4), more  than a half
(55.8%) were using protease inhibitor-based HAART, and 51.9%
of them reported to have received speciﬁc instructions from
medical doctors, on how to use their ARV regimen. Median
CD4+ cell count was 1064 cell/mm3 (IQR 793.5–1450.5). Most
children (93.5%) were followed up in CEDAP.Table 5 shows the association between children’s treatment
and 4-day children’s adherence reported by caregivers. Long-
term adherence was strongly associated to 4-day children’s
adherence, as reported by caregivers (p < 0.001).
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Table 2 – Sociodemographic characteristics of the caregiver, and the association with composed adherence and 4-day
criteria, in Salvador-Brazil, 2013–2015.
Caregiver
characteristics
N  = 77 (%) Composed
adherencea/child, N (%)
p-value 4-Day child’s adherence referred by the
caregiver, N (%)
p-value
Yes (N = 47) No (N = 30) ≥95% (N = 62) <95% (N = 15)
Age – median (IQR) 38.0 (33.5–47.5) 40.0 (34.0–52.0) 37.0 (30.2–42.2) 0.11j 40.0 (34.0–48.7) 36.0 (28.0–43.0) 0.23j
Female gender 68 (88.3) 40 (85.1) 28 (93.3) 0.46i 53 (85.5) 15 (100.0) 0.19i
Race White or
Mixedb
37 (48.1) 23 (48.9) 14 (46.7) 0.84h 28 (45.2) 9 (60.0) 0.30h
Live in the State
capital city
56  (72.7) 33 (70.2) 23 (76.7) 0.53h 44 (71.0) 12 (80.0) 0.74i
No ﬁxed incomec 41 (53.2) 24 (51.1) 17 (56.7) 0.63h 32 (51.6) 9 (60.0) 0.55h
No household
income or less
than 1 BMS d
29 (37.7) 18 (38.3) 11 (36.7) 0.88h 27 (43.5) 2 (13.3) 0.03i
Zero to four years of
formal educatione
54 (70.1) 33 (70.2) 21 (70.0) 0.98h 45 (72.6) 9 (60.0) 0.33h
Use of alcoholf 30 (39.0) 19 (40.4) 11 (36.7) 0.74h 39 (62.9) 8 (53.3) 0.49h
Caregiver
Biologically related
to the child g
63 (81.8) 39 (83.0) 24 (80.0) 0.74h 50 (80.6) 13 (86.7) 0.72i
HIV positive 41 (53.2) 25 (53.2) 16 (53.3) 0.99h 33 (53.2) 8 (53.3) 0.99h
p < 0.05 for all comparisons. PI, protease inhibitor; IQR, interquartile range.
a Adhesion deﬁned by the combination of three adherence measures (4 days child adherence ≥ 95%, pharmacy reﬁll taken in the last six months
(regular or irregular) and viral load ≤ 200 copies/mL).
b Race was self-reported.
c No Fixed Income: unemployed, housewife and self-employed; Fixed Income: employed, retired and pensioner.
d Versus between 1 and 5 BMS (Brazilian Minimum Salary)
e 0–4 years of formal education = no school/primary school; >4 years = secondary school/Higher Education
f Use of alcohol socially, 3 times a week or every day.
g Parents, grandparents, uncles, aunts.
h Test qui-square.
i Fisher exact test.
j Mann–Whitney U test.
Table 3 – HIV infected caregiver characteristics and the association with composed adherence and 4-day adherence
criteria, in Salvador-Brazil, 2013–2015.
HIV infected caregiver
characteristics
N  = 41 (%) Composed adherencea/child, N (%) p-value 4-DAY child’s adherence referred
by the caregiver, N (%)
p-value
Yes (N = 25) No (N = 16) ≥95% (N = 33) <95% (N = 8)
Regular pharmacy reﬁllb,c 15 (38.5) 14 (58.3) 1 (6.7) 0.002h 14 (43.8) 1 (14.3) 0.21h
Is long-term adherent d 12 (29.3) 12 (48.0) 0 (0.0) 0.001h 12 (36.4) 0 (0.0) 0.079h
4-day self-reported
adherence is ≥ 95%e
27 (67.5) 20 (80.0) 7 (46.7) 0.04h 23 (69.7) 4 (57.1) 0.66h
HAART without PIf 22 (56.4) 15 (62.5) 7 (46.7) 0.33g 19 (59.4) 3 (42.9) 0.67h
Revealed the HIV condition
to at least one family
member
30  (73.2) 17 (68.0) 13 (81.2) 0.47h 24 (72.7) 6 (75.0) 1.0h
p < 0.05 for all comparisons. PI, protease inhibitor.
a Adhesion deﬁned by the combination of three adherence measures (4 days child adherence > 95%, pharmacy reﬁll taken in the last six months
(regular or irregular) and viral load < 200 copies/mL).
b Pharmacy reﬁll was regular when the caregiver took his ARVs during the previous 6 months without missing.
c Data was not available for two caregivers.
d Caregiver has long-term adherence if never skipped one dose.
e Data was not available for one caregiver.
f Data was not available for 2 caregivers.
g Test qui-square.
h Fisher exact test.
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Table 4 – Children characteristics and the association to composed adherence and 4-day adherence criteria, in
Salvador-Brazil, 2013–2015.
Children
characteristics
N  = 77 (%) Composed
adherence/child, N (%)
p-value 4-Day child’s adherence
referred by the
caregiver, N (%)
p-value
Yes (N = 47) No (N = 30) ≥95% (N = 62) <95% (N = 15)
Male sex 42 (54.5) 25 (53.2) 17 (56.7) 0.76a 33 (53.2) 9 (60.0) 0.63a
Median (IQR) age in
months
94.2  (58.7–118.5) 99.7 (75.2–122.5) 78.3 (37.1–117.7) 0.13c 99.7 (60.3–123.0) 76.1 (49.3–95.8) 0.14c
ARV formulations
Liquid or powder 30 (39.0) 16 (34.0) 14 (46.7) 0.26a 22 (35.5) 8 (53.3) 0.20a
Tablet 15 (19.5) 10 (21.3) 5 (16.7) 0.61a 12 (19.4) 3 (20.0) 1.0b
Liquid + Tablet 32 (41.6) 21 (44.7) 11 (36.7) 0.48a 28 (45.2) 4 (26.7) 0.24b
Months of HAART
treatment - median
(IQR)
39.7  (24.0–67.4) 39.3 (24.1–68.5) 41.6 (20.9–66.9) 0.97c 39.2 (23.2–66.4) 47.9 (27.2–72.9) 0.36c
Use of PI-based
HAART
43  (55.8) 25 (53.2) 18 (60.0) 0.55a 33 (53.2) 10 (66.7) 0.34a
HAART has speciﬁc
instructions
40  (51.9) 24 (51.1) 16 (53.3) 0.84a 31 (50.0) 9 (60.0) 0.48a
PI, protease inhibitor; IQR, interquartile range.
a Test qui-square.
b Fisher exact test.
c Mann–Whitney U test.
Table 5 – Children characteristics and the association to composed adherence and 4-day adherence criteria, in
Salvador-Brazil, 2013–2015.
Children characteristics N = 77 (%) 4-Day child’s adherence referred by the caregiver, N (%) p-value
≥95% (N = 62) <95% (N = 15)
Median (IQR) of the Log10 viral loada 0.0 (0.0–3.7) 0.0 (0.0–3.2) 3.3 (0.0–4.0) 0.16e
The child is long-term adherentb 40 (51.9) 39 (62.9) 1 (6.7) 0.000d
Irregular pharmacy reﬁllc 44 (58.7) 33 (54.1) 11 (78.6) 0.13d
p < 0.05 for all comparisons. IQR, interquartile range.
a The Log10 viral load is not normally distributed.
b The child is long term adherent if never skipped a dose.
c Data was not available for 2 children.
d Fisher exact test.
e Mann–Whitney U test.
Discussion
There are different methods to assess children’s antiretrovi-
ral adherence. They include direct methods such as biologic
markers and body-ﬂuids assays, or indirect methods such as
self-report, caregivers-reports, pill count, pharmacy records,
and electronic drug monitoring (such as MEMS  caps).15 An
important feature of our study is that we  combined one bio-
logic marker (viral load), caregiver reports, and pharmacy reﬁll
records to produce one adherence composite, and compared
this approach with a traditional method (caregiver reports).
In one open-label study of HAART conducted in the United
States and Puerto Rico, combinations of at least two methods
(self-report and clinic attendance) to produce an adherence
evaluation tool were used.15 In developing countries caregiver
reports are commonly employed to assess children’s adher-
ence, but there are no gold standard methods for measuring
it.15–18 Results from seven studies that used caregivers reports,showed that 34–100% of caregivers reported 100% adherence
and some of them showed that caregivers generally overesti-
mate adherence in comparison with other methods.5,6,19–23
Other results on caregiver characteristics indicated that
children are more  adherent if they receive their medica-
tions from foster parents rather than the biological ones, or
other relatives.7,24 We  did not ﬁnd associations between these
variables (p = 0.23). A Brazilian cross-sectional study also eval-
uated the impact of caregivers’ factors on children’s adherence
and concluded that children’s non-adherence was signiﬁ-
cantly associated with caregivers low-educational level and
to absence of biological parents.25
In this study, we  detected an opposite association: the large
majority of the caregivers had no income or received less than
a minimum wage, but children under their care had a high rate
of optimal adherence (≥95%), in the 4-day caregiver report. A
reasonable explanation for this result relies on the fact that
caregivers having a better monthly income, probably have a
regular work, and would have less available time to care for the
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hildren under treatment. On the other hand, several studies
ndicate that ﬁnancial constraint can be an obstacle to main-
ain child’s adherence and collect medication on time. Some
f the reasons are the distance barrier or lack of access to
asy transportation to HIV clinic, forcing patients/caregivers to
hoose between paying for transportation or using the money
or food.10,26,27 Another potential explanation for this dis-
repancy could be the low accuracy of such evaluations, for
ifferent populations.
An observational cross-sectional study conducted in Brazil
valuated 108 children and adolescents. Adherence was
ssessed using a questionnaire and pharmacy reﬁll register.
atients and/or their caregivers were asked about the admin-
stration of prescribed medication in the last 24 h or last seven
ays. The prevalence of non-adherence was 45.4% based on
harmacy reﬁll and the authors concluded that this method
as a high sensitivity to detect non-adherence.28
It is known that caregiver factors are important to pedi-
tric adherence, which is directly or indirectly inﬂuenced by
he resources and efﬁcacy of care provided by their caregivers.
 qualitative study conducted with 71 maternal caregivers of
IV infected children, administered an open-ended interview
n questions concerning caregiving activities. Seventeen per-
ent of the mothers with HIV, provided information about their
wn non-adherence. The low rate of mothers’ adherence in
hat study negatively inﬂuenced their children’s adherence.29
In a multicenter, comparative trial, children older than 10
ears were found to have better adherence than younger chil-
ren, although the number of children in this group was small
nd most of them younger than 12 years.6 Our results did
ot detect any association between these two variables (com-
osed adherence and 4-day child’s adherence referred by the
aregiver ≥95%).
Another challenging aspect for pediatric patients’ adher-
nce is the administration of the correct dose of each ARV
rug, due to limited availability of ﬁxed-dose formulations,
nd differences in the way drugs are metabolized. Combin-
ng different drugs in appropriate formulations is particularly
omplex for infants and children, and often it results in under
r overdosing. Moreover, dividing pills into halves or quarters
oes not ensure adequate dosing for children.30 As showed
n this study, better adherence was observed in children tak-
ng pills only, compared to liquid formulations. Although this
ssociation did not reach statistical signiﬁcance, it was prob-
bly due to the small sample size.
In a prospective cohort study, ART adherence levels and
he ability of adherence measures to predict viral suppres-
ion among HIV infected children were evaluated. Regression
odeling indicated that adherence rate was inversely, but not
igniﬁcantly, associated with log viral load at enrollment or
-month visit, similarly to our ﬁndings.31 There was a sig-
iﬁcant association between long-term and 4-day children’s
dherence, as referred by caregiver. Long-term adherence in
ur study means that the child never missed a dose, accord-
ng to caregiver’s report, and could be deﬁned as perfect
dherence.
The limitations of our study include the cross-sectional
esign, which did not allow for the evaluation of adherence
ver time, the use of caregivers’ self-report adherence that can
verestimate the true prevalence of adherence, and the small6;2 0(5):429–436 435
sample size, which limited our ability to investigate interac-
tions among study variables by multivariate analysis.
However, a strong component of this study is the composed
adherence, which showed that, the 4-day child’s adherence
referred only by the caregiver, could not be trusted as the only
way to assess adherence, as used in other studies. This adher-
ence evaluation tool demonstrated to be stronger than other
methods used before. It is easy to apply and requires only a
biological marker (plasma HIV-1 viral load), in association to
pharmacy records and a self-reported questionnaire. Further
studies are required to validate and conﬁrm the usefulness of
this tool.
Taken together, our results suggest the need of adherence
improvement in HIV infected children, especially those who
depend on caregivers. It is clear that some caregiver’s charac-
teristics can inﬂuence children’s adherence. Actions focused
on caregivers’ education and reinforcement of the need of
correct use of antiretrovirals are urgently needed in order to
improve outcomes of HIV infected children.
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